Patents by Inventor Mitchell Elliot Reff

Mitchell Elliot Reff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY
    Publication number: 20090226430
    Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
    Type: Application
    Filed: February 29, 2008
    Publication date: September 10, 2009
    Applicant: Biogen Idec Inc.
    Inventors: Nabil HANNA, Roland Anthony Newman, Mitchell Elliot Reff
  • RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY
    Publication number: 20090221036
    Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
    Type: Application
    Filed: July 2, 2008
    Publication date: September 3, 2009
    Applicant: Biogen Idec Inc.
    Inventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
  • Recombinant anti-CD4 antibodies for human therapy
    Patent number: 7452534
    Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
    Type: Grant
    Filed: July 10, 2000
    Date of Patent: November 18, 2008
    Assignee: Biogen Idec Inc.
    Inventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
  • Recombinant anti-CD4 antibodies for human therapy
    Patent number: 7338658
    Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: March 4, 2008
    Assignee: Biogen Idec Inc.
    Inventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
  • Recombinant anti-CD4 antibodies for human therapy
    Publication number: 20030077275
    Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
    Type: Application
    Filed: August 5, 2002
    Publication date: April 24, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
  • Recombinant anti-CD4 antibodies for human therapy
    Patent number: 6136310
    Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
    Type: Grant
    Filed: September 6, 1995
    Date of Patent: October 24, 2000
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff